Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 14, 2019updated 15 Mar 2019 5:20am

Pharma industry M&A deals in Q4 2018 total $11.95bn in United States

Total US pharma industry M&A deals in Q4 2018 worth $11.95bn were announced, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 27.2% over the previous quarter and a drop of 22.6% when compared with the last four-quarter average of $15.43bn.

The United States held an 81.5% share of the global pharma industry M&A deal value that totalled $14.66bn in Q4 2018.

In terms of deal activity, the United States recorded 70 deals during Q4 2018, marking a rise of 6.1% over the previous quarter and a rise of 27.3% over the last four-quarter average.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

US pharma industry M&A deals in Q4 2018: Top deals

The top five pharma industry M&A deals accounted for 90.4% of the overall value during Q4 2018.

The combined value of the top five pharma industry M&A deals stood at $10.8bn, against the overall value of $11.95bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.

In second place was the $2.1bn acquisition of Endocyte by Novartis and in third place was Swedish Orphan Biovitrum’s $1.97bn asset transaction with AstraZeneca.

The $1.2bn acquisition of Pacific Biosciences of California by Illumina and AMAG Pharmaceuticals and Magellan Merger Sub’s acquisition of Perosphere Pharmaceuticals for $433.2m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU